In Veritas Valuation
| IVME Stock | USD 0.0001 0.00 0.00% |
In Veritas seems to be overvalued based on Macroaxis valuation methodology. Our model calculates the value of In Veritas Medical from examining the firm fundamentals such as Net Income of (3.67 M), price to earning of (0.01) X, and Current Valuation of 8.6 K as well as evaluating its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that In Veritas' price fluctuation is very steady at this time. Calculation of the real value of In Veritas Medical is based on 3 months time horizon. Increasing In Veritas' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the IVME stock is determined by what a typical buyer is willing to pay for full or partial control of In Veritas Medical. Since In Veritas is currently traded on the exchange, buyers and sellers on that exchange determine the market value of IVME Stock. However, In Veritas' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.0E-4 | Real 8.4E-5 | Hype 1.0E-4 | Naive 1.0E-4 |
The real value of IVME Stock, also known as its intrinsic value, is the underlying worth of In Veritas Medical Company, which is reflected in its stock price. It is based on In Veritas' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of In Veritas' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of In Veritas Medical helps investors to forecast how IVME stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of In Veritas more accurately as focusing exclusively on In Veritas' fundamentals will not take into account other important factors: In Veritas Total Value Analysis
In Veritas Medical is currently expected to have valuation of 8.6 K with market capitalization of 8.61 K, debt of 1.21 M, and cash on hands of . Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the In Veritas fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
8.6 K | 8.61 K | 1.21 M |
In Veritas Asset Utilization
One of the ways to look at asset utilization of IVME is to check how much profit was generated for every dollar of assets it reports. In Veritas owns a negative utilization of current and long term assets of -6.48 %, losing $0.0648 for each dollar of current and long term assets held by the firm. Discouraging asset utilization attests that the company is being less productive with each dollar of current and long term assets it owns. Strictly speaking, asset utilization of In Veritas Medical shows how wasteful it operates for each dollar spent on its current and long term assets.In Veritas Profitability Analysis
Net Loss for the year was (3.67 M) with profit before overhead, payroll, taxes, and interest of 0.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates In Veritas' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in In Veritas and how it compares across the competition.
About In Veritas Valuation
The stock valuation mechanism determines In Veritas' current worth on a weekly basis. Our valuation model uses a comparative analysis of In Veritas. We calculate exposure to In Veritas's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of In Veritas's related companies.In Veritas Medical Diagnostics, Inc., a development stage company, engages in the research and development of medical devices with near-patient testing applications. It was formerly known as In Vivo Medical Diagnostics, Inc. and changed its name to In Veritas Medical Diagnostics, Inc. in 2005. IN Veritas operates under Shell Companies classification in the United States and is traded on OTC Exchange. It employs 7 people.
Complementary Tools for IVME Stock analysis
When running In Veritas' price analysis, check to measure In Veritas' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy In Veritas is operating at the current time. Most of In Veritas' value examination focuses on studying past and present price action to predict the probability of In Veritas' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move In Veritas' price. Additionally, you may evaluate how the addition of In Veritas to your portfolios can decrease your overall portfolio volatility.
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |